This category needs an editor. We encourage you to help if you are qualified.
Volunteer, or read more about what this involves.
Related categories

729 found
Order:
1 — 50 / 729
Material to categorize
  1. Lowering Restrictions on Performance Enhancing Drugs in Elite Sports.Rory Warwick Collins - 2017 - Inquiries Journal 9 (3).
    This article argues that performance enhancing drugs ought to be allowed across all elite sporting competitions for athletes over the age of 16 so long as consuming them does not pose a significant risk to their health. I begin with a brief explanation of the current state of PED use in professional sports before assessing the prospect of allowing PEDs by three widely accepted measures of ethical merit: well-being, autonomy, and justice. I end with a critique of the World Anti-Doping (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  2. Ethics and Drug Testing in Human Beings.Joseph Mahon - 1987 - Royal Institute of Philosophy Lectures 22:199-211.
    In late May 1984, Irish citizens were perturbed to hear that a thirty-one year old man died while participating, as a paid volunteer, in a clinical drug trial at the Institute of Clinical Pharmacology in Dublin. At the inquest, held in September 1984, the State Pathologist, Dr John Harbison, affirmed that the cause of death was the reaction of the trial drug Eproxindine 4/0091 with a major tranquillizer which had been given less than fifteen hours earlier as part of regular (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  3. Adolescent and Parent Perspectives on Ethical Issues in Youth Drug Use and Suicide Survey Research.Celia B. Fisher - 2003 - Ethics and Behavior 13 (4):303-332.
    The contributions of adolescent and parent perspectives to ethical planning of survey research on youth drug use and suicide behaviors are highlighted through an empirical examination of 322 7th-12th graders' and 160 parents' opinions on questions related to 4 ethical dimensions of survey research practice: evaluating research risks and benefits, establishing guardian permission requirements, developing confidentiality and disclosure policies, and using cash incentives for recruitment. Generational and ethnic variation in response to questionnaire items developed from discussions within adolescent and parent (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  4. Key Opinion Leaders and Pediatric Antidepressant Overprescribing.Jon Jureidini & Leemon McHenry - 2009 - Psychotherapy and Psychosomatics 78:197-201.
    The lingering controversy concerning the usefulness and safety of antidepressants for children and adolescents is likely to confuse clinicians. Recent papers perpetuate the claim that antidepressants are shown to be safe and effective in randomised controlled trials. Others claim that antidepressants have been shown to prevent suicides. In this editorial we address the manipulation of outcomes that result from academics’ alliance with industry. We explain how industry and key opinion leaders have distorted the clinician’s perception of the safety and usefulness (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  5. On the Origin of Great Ideas: Science in the Age of Big Pharma.Leemon B. McHenry - 2005 - Hastings Center Report 35 (6):17-19.
    This case study reports an instance of SmithKline Beecham's behind-the-scenes ghostwriting a letter to the editor in a medical journal article in the name of an academic physician. In order to respond to criticism that paroxetine caused severe withdrawal effects, SmithKline Beecham's marketing department hired a PR firm to ghostwrite three separate letters to spin a favorable impression of paroxetine vs fluoxetine and published one in the Journal of Clinical Psychiatry.
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  6. Industry-Corrupted Psychiatric Trials.Leemon McHenry, Jon Jureidini & Jay Amsterdam - 2017 - Psychiatria Polska 51 (6):993-1008.
    The goal of this paper is to expose the research misconduct of pharmaceutical industry-sponsored clinical trials via three short case studies of corrupted psychiatric trials that were conducted in the United States. We discuss the common elements that enable the misrepresentation of clinical trial results including ghostwriting for medical journals, the role of key opinion leaders as co-conspirators with the pharmaceutical industry and the complicity of top medical journals in failing to uphold standards of science and peer review. We conclude (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  7. The Citalopram CIT-MD-18 Pediatric Depression Trial: A Deconstruction of Medical Ghostwriting, Data Manipulation and Academic Malfeasance.Leemon McHenry, Jon Jureidini & Jay Amsterdam - 2016 - International Journal of Risk and Safety in Medicine 28:33-43.
    This paper is a deconstruction of a ghostwritten report of a randomized, double-blind, placebo-controlled efficacy and safety trial of citalopram in depressed children and adolescents conducted in the United States. Court documents revealed that protocol-specified outcome measures showed no statistically significant difference between citalopram and placebo. However, the published article concluded that citalopram was safe and significantly more efficacious than placebo for children and adolescents, with possible adverse effects on patient safety.
    Remove from this list  
     
    Export citation  
     
    Bookmark   1 citation  
  8. At Law: FDA's Compassion for Desperate Drug Companies.George J. Annas - 1990 - Hastings Center Report 20 (1):35.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  9. Confronting the Other.Peter Steinfels - 1972 - Hastings Center Report 2 (5):4.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  10. Book Review: Prescription Drug Abuse and DependenceGreenfieldDaniel P., Ed., Prescription Drug Abuse and Dependence: How Prescription Drug Abuse Contributes to the Drug Abuse Epidemic : 170 Pp. [REVIEW]Bonnie Wilford - 1996 - Journal of Law, Medicine and Ethics 24 (1):62-64.
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  11. Recent Developments in Health Law: FDA and Drug Safety: New Tufts Study Challenges Critics of the Prescription Drug User Fee Act.Rochelle Lee - 2006 - Journal of Law, Medicine and Ethics 34 (1):131-134.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  12. Recent Developments in Health Law: FDA and Drug Safety: New Tufts Study Challenges Critics of the Prescription Drug User Fee Act.Rochelle Lee - 2006 - Journal of Law, Medicine and Ethics 34 (1):131-134.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  13. Pharmaceutical Firms and the Right to Health.Thana Cristina de Campos & Thomas Pogge - 2012 - Journal of Law, Medicine and Ethics 40 (2):183-187.
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  14. Institutional Corruption and the Pharmaceutical Policy.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):544-552.
    Today, the goals of pharmaceutical policy and medical practice are often undermined due to institutional corruption — that is, widespread or systemic practices, usually legal, that undermine an institution's objectives or integrity. In this symposium, 16 articles investigate the corruption of pharmaceutical policy, each taking a different look at the sources of corruption, how it occurs, and what is corrupted. We will see that the pharmaceutical industry's own purposes are often undermined. Furthermore, pharmaceutical industry funding of election campaigns and lobbying (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  15. ‘Drugs That Make You Feel Bad’? Remorse-Based Mitigation and Neurointerventions.Jonathan Pugh & Hannah Maslen - 2017 - Criminal Law and Philosophy 11 (3):499-522.
    In many jurisdictions, an offender’s remorse is considered to be a relevant factor to take into account in mitigation at sentencing. The growing philosophical interest in the use of neurointerventions in criminal justice raises an important question about such remorse-based mitigation: to what extent should technologically facilitated remorse be honoured such that it is permitted the same penal significance as standard instances of remorse? To motivate this question, we begin by sketching a tripartite account of remorse that distinguishes cognitive, affective (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  16. Demand for a Medicare Prescription Drug Benefit: Exploring Consumer Preferences Under a Managed Competition Framework.Richard R. Cline & David A. Mott - 2003 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 40 (2):169-183.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  17. Demand for a Medicare Prescription Drug Benefit: Exploring Consumer Preferences Under a Managed Competition Framework.Richard R. Cline & David A. Mott - 2003 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 40 (2):169-183.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  18. Perverse Incentives in the Medicare Prescription Drug Benefit.David McAdams & Michael Schwarz - 2007 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 44 (2):157-166.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  19. Perverse Incentives in the Medicare Prescription Drug Benefit.David McAdams & Michael Schwarz - 2007 - Inquiry: The Journal of Health Care Organization, Provision, and Financing 44 (2):157-166.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  20. Responding to Vulnerability: The Case of Injection Drug Use.Elizabeth Ben-Ishai - 2012 - International Journal of Feminist Approaches to Bioethics 5 (2):39-63.
    "Before they were 'junkies,' they were kids." The words appear on a poster, beneath a montage of photographs of children and the text: "Save Insite." Insite, located in Vancouver, Canada, is North America's first and only supervised injection facility (SIF). At Insite, people who use injection drugs can inject previously obtained drugs, such as heroin and cocaine, under medical supervision, using sterile equipment provided by this government-run facility. Opened under the auspices of a three-year exemption from federal drug laws in (...)
    Remove from this list   Direct download (7 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  21. Raising the Barriers to Access to Medicines in the Developing World – The Relentless Push for Data Exclusivity.Diependaele Lisa, Cockbain Julian & Sterckx Sigrid - 2017 - Developing World Bioethics 17 (1):11-21.
    Since the adoption of the WTO-TRIPS Agreement in 1994, there has been significant controversy over the impact of pharmaceutical patent protection on the access to medicines in the developing world. In addition to the market exclusivity provided by patents, the pharmaceutical industry has also sought to further extend their monopolies by advocating the need for additional ‘regulatory’ protection for new medicines, known as data exclusivity. Data exclusivity limits the use of clinical trial data that need to be submitted to the (...)
    Remove from this list   Direct download (7 more)  
     
    Export citation  
     
    Bookmark  
  22. Governing the Injecting Drug User.Ian Walmsley - 2012 - History of the Human Sciences 25 (4):90-107.
    This article offers a critical contribution to the debate on a problematic ‘type’ of injecting drug use referred to as needle fixation. At the heart of this debate, is a questioning of the existence, prevalence and usefulness of the needle fixation concept for academics and drug treatment practitioners working with injecting drug users. The aim of this article is to extend and develop this discussion by examining the historical conditions of the needle fixation discourse. Drawing upon Michel Foucault’s concept of (...)
    Remove from this list   Direct download (7 more)  
     
    Export citation  
     
    Bookmark  
  23. The Power of Pills: Social, Ethical & Legal Issues in Drug Development, Marketing & Pricing – Edited by Jillian C. Cohen, Patricia Illingworth & Udo Schüklenk.Steven Lewis - 2009 - Developing World Bioethics 9 (1):43-45.
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  24. Review of Leonard J. Weber, Profits Before People? Ethical Standards and the Marketing of Prescription Drugs.1. [REVIEW]Jerome P. Kassirer - 2007 - American Journal of Bioethics 7 (3):54-55.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  25. The Physician and the Pharmaceutical Detail Man: An Ethical Analysis.Brian Kaatz & Jerome Freeman - 1987 - Journal of Medical Humanities 8 (1):34-39.
    The relationship between the physician and the pharmaceutical detail man is discussed. Specific emphasis is given to an analysis of the ethical implications that this relationship has for patient care.
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  26. GlaxoSmithKline and Developing Country Access to Essential Medicines.N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):97-121.
    The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world’s second largest pharmaceutical company, GlaxoSmithKline. GSK also became the world’s leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK (...)
    Remove from this list   Direct download (7 more)  
     
    Export citation  
     
    Bookmark  
  27. Trade Rules, Intellectual Property, and the Right to Health.Lisa Forman - 2007 - Ethics and International Affairs 21 (3):337-357.
    In perpetuating and exacerbating restricted access to essential medicines, current trade-related intellectual property rules on medicines may violate core human rights to health and medicines. In this light, there should be serious questions about their necessity, and their justification should be critically assessed from the perspective of human rights standards.
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  28. Access to Medicines and the Rhetoric of Responsibility.Christian Barry & Kate Raworth - 2002 - Ethics and International Affairs 16 (2):57-70.
    In Africa fewer than 50,000 people—less than 2 percent of the people in need—currently receive ARV therapy. These facts have elicited strongly divergent reactions, and views about the appropriate response to this crisis have varied widely.
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  29. Pharmacists' and Doctors’ Perception of Pharmaceutical Representative’s Ethical Practices of Drug Promotion in Romania. A Comparative Study.Laszlo-Zoltan Sztankovszky, Camelia Soponaru, Magdalena Iorga & Vasile Astarastoae - 2015 - Postmodern Openings 6 (1):189-199.
    The purpose of the study is to identify perception of doctors and pharmacists on drug promotion practices adopted by pharmaceutical representatives. Material and Methods: A total of 72 pharmacists and 65 doctors responded to a questionnaire about their perceptions on drug promotion practices by pharmaceutical representatives, both in relation to pharmacists and doctors in the relationship. Variables such as age, work environment, seniority, were considered. Of all pharmacists who responded to the questionnaire, a percentage of 47.8% say they have no (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  30. Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Healthcare by Peter Gøtzsche.Justin B. Biddle - 2016 - Kennedy Institute of Ethics Journal 26 (2):40-43.
    From the title, Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Healthcare, Peter Gøtzsche makes the thesis of his book very clear. Not only does the pharmaceutical industry contribute to detrimental health outcomes through biased research, deceptive marketing, and disease mongering, but the industry’s business model meets the criteria of an organized criminal operation. Gøtzsche argues for this in two parts. First, he defines organized crime by drawing upon the United States Organized Crime Control Act of 1970, the (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  31. Body-Self Dualism in Contemporary Ethics and Politics.Patrick Lee & Robert P. George - 2007 - Cambridge University Press.
    Profoundly important ethical and political controversies turn on the question of whether biological life is an essential aspect of a human person, or only an extrinsic instrument. Lee and George argue that human beings are physical, animal organisms - albeit essentially rational and free - and examine the implications of this understanding of human beings for some of the most controversial issues in contemporary ethics and politics. The authors argue that human beings are animal organisms and that their personal identity (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark   26 citations  
  32. Pharmaceutical Company Corruption and the Moral Crisis in Medicine.Sharon Batt - 2016 - Hastings Center Report 46 (4):10-13.
    A much-debated series of articles in the New England Journal of Medicine in May 2015 labeled the pharmaceutical industry's critics “pharmascolds.” Having followed the debate for two decades, I count myself among the scolds. The weight of the evidence overwhelmingly supports the claim that pharmaceutical policy no longer serves the public interest; the central questions now are how this happened and what to do about it. I approached three of the most recent books on the industry with these questions in (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  33. The Disposable Author:How Pharmaceutical Marketing Is Embraced Within Medicine's Scholarly Literature.Alastair Matheson - 2016 - Hastings Center Report 46 (4):31-37.
    The best studies on the relationship between pharmaceutical corporations and medicine have recognized that it is an ambiguous one. Yet most scholarship has pursued a simpler, more saleable narrative in which pharma is a scheming villain and medicine its maidenly victim. In this article, I argue that such crude moral framing blunts understanding of the murky realities of medicine's relationship with pharma and, in consequence, holds back reform. My goal is to put matters right in respect to one critical area (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  34. Roy Church and E. M. Tansey, Burroughs Wellcome & Co.: Knowledge, Trust and Profit, and the Transformation of the British Pharmaceutical Industry, 1880–1940. Lancaster: Crucible, 2007. Pp. Xxvii+564. ISBN 978-1-905-472-07-9. £19.99. [REVIEW]Claire Jones - 2009 - British Journal for the History of Science 42 (2):288.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  35. Jonathan Liebenau. Medical Science and Medical Industry. The Formation of the American Pharmaceutical Industry. London: Macmillan, 1987. Pp Ix + 207. ISBN 0-333-41742-9, £29.50. - John P. Swann. Academic Scientists and the Pharmaceutical Industry. Cooperative Research in Twentieth Century America. Baltimore: The Johns Hopkins University Press, 1988. Pp Xi + 249. ISBN 0-8018-3558-5, £22.50. [REVIEW]Peter Morris - 1989 - British Journal for the History of Science 22 (4):442-444.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  36. L ESLEY R ICHMOND, J ULIE S TEVENSON and A LISON T URTON , The Pharmaceutical Industry: A Guide to Historical Records. Aldershot: Ashgate, 2003. Pp. Ix+561. ISBN 0-7546-3352-7. £55.00. [REVIEW]Peter Morris - 2006 - British Journal for the History of Science 39 (1):144-145.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  37. Academic Scientists and the Pharmaceutical Industry: Cooperative Research in Twentieth-Century America. John P. Swann.Leon Gortler - 1990 - Isis 81 (1):136-137.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  38. Medical Science and Medical Industry: The Formation of the American Pharmaceutical Industry. Jonathan Liebenau.John P. Swann - 1988 - Isis 79 (3):521-523.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  39. Old Drugs in New BottlesResearches in the History of Pharmaceutical ChemistryGerald Schröder Robert Bohlmann Winfred Schröder Dietrich Arends Erika Hickel Wolfgang Schneider Herbert Wietschoreck Bhulabhai Patel Christian Wehle Mechthild Krüger Horst Matthias Real.Robert P. Multhauf - 1972 - Isis 63 (3):408-412.
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  40. Feeling Is Believing: Evaluative Conditioning and the Ethics of Pharmaceutical Advertising.Paul Biegler & Patrick Vargas - 2016 - Journal of Bioethical Inquiry 13 (2):271-279.
    A central goal in regulating direct-to-consumer advertising of prescription pharmaceuticals is to ensure that explicit drug claims are truthful. Yet imagery can also alter viewer attitudes, and the degree to which this occurs in DTCA is uncertain. Addressing this data gap, we provide evidence that positive feelings produced by images can promote favourable beliefs about pharmaceuticals. We had participants view a fictitious anti-influenza drug paired with unrelated images that elicited either positive, neutral or negative feelings. Participants who viewed positive images (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  41. Ethical Relation Between Physicians and Pharmaceutical Industries in the Perspectives of Bangladesh.Shahinul Alam, Nahiduz Saman, Monsur Hallaj Hallaj, Jahangir Ul Alam & Shoaib Momen Majumder - 2015 - Bangladesh Journal of Bioethics 6 (1):1-5.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  42. Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines.Joo-Young Lee & Paul Hunt - 2012 - Journal of Law, Medicine and Ethics 40 (2):220-233.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  43. Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines.Lisa Cosgrove & Emily E. Wheeler - 2013 - Journal of Law, Medicine and Ethics 41 (3):644-653.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   7 citations  
  44. Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health.Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander - 2012 - Journal of Law, Medicine and Ethics 40 (2):234-250.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  45. Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):654-664.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   10 citations  
  46. The Ethics of Pharmaceutical Research Funding: A Social Organization Approach.Garry C. Gray - 2013 - Journal of Law, Medicine and Ethics 41 (3):629-634.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  47. Pharmaceutical Companies Vs. The State: Who is Responsible for Post-Trial Provision of Drugs in Brazil?Daniel Wei L. Wang & Octavio Luiz Motta Ferraz - 2012 - Journal of Law, Medicine and Ethics 40 (2):188-196.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  48. Brightening Up: The Effect of the Physician Payment Sunshine Act on Existing Regulation of Pharmaceutical Marketing.Igor Gorlach & Genevieve Pham-Kanter - 2013 - Journal of Law, Medicine and Ethics 41 (1):315-322.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  49. Five Un-Easy Pieces of Pharmaceutical Policy Reform.Marc A. Rodwin - 2013 - Journal of Law, Medicine and Ethics 41 (3):581-589.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  50. Reforming Pharmaceutical Industry-Physician Financial Relationships: Lessons From the United States, France, and Japan.Marc A. Rodwin - 2011 - Journal of Law, Medicine and Ethics 39 (4):662-670.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
1 — 50 / 729